Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome I

ABSTRACT: Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome I

PROVIDER: PRJNA1049467 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

| PRJNA910594 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

| PRJNA1049466 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome III

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome III

| PRJNA1096332 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Individuals with Down syndrome have a increased likelihood of suffering from inflammatory and autoimmune conditions, due to the presence of four interferon receptors on chromosome 21. Transcription of genes plays a key role in the interferon response, and the Mediator kinases, CDK8 and CDK19, are essential in potentiating this transcription. Given the role CDK8/19 play in the interferon response, and the fact that selective inhibitors of these kinases exist (such as Cortistatin A), it is possible that targetting Mediator kinase activity may alleviate symptoms of chronic inflammation in Down syndrome.

2023-09-12 | GSE220652 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

2024-09-01 | GSE249549 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome III

2025-02-04 | GSE263239 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome I

2025-01-01 | GSE249548 | GEO

Transcriptional Regulation of Protein Synthesis by Mediator Kinase Represents a Therapeutic Vulnerability in MYC-driven Medulloblastoma

Project description:MYC-driven medulloblastoma (MB) is a highly aggressive cancer type with poor prognosis and limited treatment options. Through CRISPR-Cas9 screening of MB cell lines, we identified the Mediator-associated kinase CDK8 as a critical regulator of MYC-driven MB. Loss of CDK8 substantially reduces MYC expression, induces pronounced transcriptional changes, suppresses monosome assembly, and decreases ribosome biogenesis and protein synthesis, consequently inhibiting MB growth. Mechanistically, CDK8 regulates the occupancy of RNA polymerase II at specific chromatin loci, facilitating an epigenetic alteration that promotes the transcriptional regulation of ribosomal genes. Targeting CDK8 effectively diminishes the stem-like neoplastic cells characterized by hyperactive ribosome biogenesis. Furthermore, we demonstrated that the combined inhibition of CDK8 and mTOR synergizes to optimize therapeutic outcomes in vivo and in vivo. Overall, our findings establish a connection between CDK8-mediated transcriptional regulation and mRNA translation, suggesting a promising new therapeutic approach that targets the protein synthesis for MYC-driven MB.

2024-12-01 | GSE280973 | GEO

LNK suppresses interferon signaling in melanoma

Project description:LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive signaling of the RAS-RAF-MEK pathway. Elevated LNK enhances cell growth and survival in adverse conditions. Forced expression of LNK inhibits signaling by interferon-STAT1 and suppresses interferon (IFN) induced cell cycle arrest and cell apoptosis. In contrast, silencing LNK expression by either shRNA or CRISPR-Cas9 potentiates the killing effect of IFN. The IFN-LNK signaling is tightly regulated by a negative feedback mechanism; melanoma cells exposed to IFN upregulate expression of LNK to prevent overactivation of this signaling pathway. Our study reveals an unappreciated function of LNK in melanoma and highlights the critical role of the IFN-STAT1-LNK signaling axis in this potentially devastating disease. LNK may be further explored as a potential therapeutic target for melanoma immunotherapy.

2019-04-29 | GSE127333 | GEO

Force expression LNK suppresses interferon Gamma signaling

2019-03-31 | GSE127764 | GEO